NAVAMEDIC ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 34 NOK | +2.72% |
|
+1.80% | -7.36% |
| May. 06 | Navamedic Rolls Out Erectile Dysfunction Drug in Sweden | MT |
| Apr. 30 | Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 592M 55.15M | Sales 2025 * | 690M 64.32M | Capitalization | 593M 55.22M |
|---|---|---|---|---|---|
| Net income 2024 * | 24M 2.24M | Net income 2025 * | 61M 5.68M | EV / Sales 2024 * | 0.96 x |
| Net cash position 2024 * | 21.73M 2.02M | Net cash position 2025 * | 101M 9.43M | EV / Sales 2025 * | 0.71 x |
| P/E ratio 2024 * |
24.8
x | P/E ratio 2025 * |
10.1
x | Employees | 45 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.33% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.72% | ||
| 1 week | +1.80% | ||
| Current month | +4.94% | ||
| 1 month | +0.29% | ||
| 3 months | -10.29% | ||
| 6 months | -7.86% | ||
| Current year | -7.36% |
1 week
32.80
34.00
1 month
30.5034.70
Current year
30.5040.00
1 year
30.5043.90
3 years
19.5043.90
5 years
13.5043.90
10 years
8.0043.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 18-05-31 | |
Lars Hjarrand
DFI | Director of Finance/CFO | 51 | 19-12-08 |
| Chief Tech/Sci/R&D Officer | - | 18-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Narve Reiten
BRD | Director/Board Member | 63 | - |
Terje Bakken
CHM | Chairman | 58 | 18-12-30 |
Jostein Davidsen
BRD | Director/Board Member | 65 | 17-01-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 34 | +2.72% | 13,331 |
| 24-05-15 | 33.1 | -1.49% | 17,639 |
| 24-05-14 | 33.6 | +0.60% | 3,792 |
| 24-05-13 | 33.4 | +0.91% | 13,041 |
| 24-05-10 | 33.1 | -0.90% | 17,880 |
Real-time Oslo Bors, May 16, 2024 at 10:45 am EDT
More quotes
Navamedic ASA is a Norway-based pharmaceutical company. It is a supplier of products delivered to hospitals and pharmacies. Navamedicâs product portfolio consists of prescription and Over The Counter (OTC) pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. The Companyâs offering is divided into four product areas: Consumer Health, Specialty Pharma, Medical Nutrition and Branded Generics. The Company has one business segment which is the Pharma division. Navamedic ASA is present in all Nordic countries, the Baltics and Benelux. The Company has two subsidiaries, Navamedic AB, through which the Company distributes more than 40 products and a Norway-based Novicus Pharma AS.
Sector
Pharmaceuticals
Calendar
2024-06-03
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
34
NOK
Average target price
49
NOK
Spread / Average Target
+44.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.36% | 55.38M | |
| +32.36% | 694B | |
| +29.64% | 593B | |
| -1.60% | 371B | |
| +20.07% | 331B | |
| +6.04% | 290B | |
| +14.43% | 239B | |
| +10.26% | 209B | |
| -3.39% | 209B | |
| +9.27% | 169B |
- Stock Market
- Equities
- NAVA Stock
